Partial
Not Aligned
Patient Risk:
Moderate
Summary
Several general statements are broadly consistent with label concepts (IV MRI use, BBB/vascular disruption indication, kidney function screening/caution, retention minimization, hypersensitivity, injection-site reactions). However, key specifics are missing or not label-supported: multiple tumor/infection indications are not present in the provided labeling excerpt; dosing specificity is not reflected; and some phrasing implies broader or uncertain uses. Overall alignment is partial.
Category Scores
Accurate Statements
Gadoterate meglumine is a gadolinium-based contrast agent (GBCA) used in MRI.
Label describes Clariscan (gadoterate meglumine) as a gadolinium-based contrast agent indicated for intravenous use with MRI.
Gadoterate meglumine is given by injection before or during an MRI scan.
Label indicates intravenous bolus injection administration for MRI (2.1). Timing as 'before or during' is consistent but not explicitly detailed in the provided excerpts.
Gadolinium contrast is used to enhance visibility of areas that may have abnormal blood flow or a disrupted barrier.
Indication: detect and visualize areas with disruption of the BBB and/or abnormal vascularity (1).
Gadoterate meglumine is administered by healthcare professionals via an injection for the MRI exam.
Clariscan is administered as an intravenous bolus injection (2.1). The 'healthcare professional' wording is not explicit in excerpts but does not directly conflict.
Timing and dose of gadoterate meglumine depend on the scan type and patient factors, including kidney function.
Label provides a recommended dose (0.2 mL/kg) and includes renal-impairment-related warnings/NSF risk; however, 'scan type' dependence and 'dose depends on kidney function' are not supported (see unsupported/omission).
People with kidney problems need extra caution with any gadolinium-based contrast agent.
Label warns GBCAs increase NSF risk among patients with impaired elimination; avoid use unless essential (5.2).
Clinicians typically assess kidney function before giving gadolinium contrast.
Label says to screen patients for acute kidney injury and other conditions that may reduce renal function (5.2).
Clinicians particularly assess kidney function in patients with known chronic kidney disease or at higher risk for kidney impairment.
Label highlights highest NSF risk in chronic severe kidney disease and acute kidney injury and states to screen patients (5.2).
Gadoterate meglumine can cause side effects.
Label includes warnings and adverse reactions sections (6).
Mild side effects such as nausea, headache, or injection-site reactions may occur with gadoterate meglumine.
Injection-site reactions are mentioned in 5.6, but nausea/headache are not shown in the provided excerpts (unsupported/absent).
The exact frequency and types of side effects are determined by the prescribing information and patient context.
General alignment with label having adverse reactions sections; not a specific label statement in excerpts.
There are multiple GBCA options used for MRI.
Label compares retention among macrocyclic GBCAs (5.4), indicating multiple GBCA products exist.
GBCA options have different stability profiles and dosing considerations.
Label excerpt does not discuss stability profiles or dosing differences.
A clinician chooses a GBCA based on the MRI indication, patient risk factors (particularly kidney function), and local availability.
Label supports considering renal impairment/NSF risk and using Clariscan for IV MRI indication, but does not mention local availability or explicit clinician selection framework.
Gadolinium agents differ in their chemical structure and stability.
Label refers to 'macrocyclic GBCAs' and compares retention among specific agents (5.4), but does not explicitly address chemical structure/stability differences in dosing terms.
The choice between gadolinium agents is guided by clinical guidelines and product labeling in the region.
Label refers to use conditions and warnings; does not mention clinical guidelines or 'in the region.'
Unsupported Statements
Gadoterate meglumine is given by injection before or during an MRI scan.
Label excerpt specifies IV bolus injection for MRI but does not explicitly state timing as 'before or during' in the provided text.
Gadolinium contrast is used for certain tumors, inflammation/infection, and other lesions.
Provided label excerpts do not include indications beyond detecting/visualizing disruption of the BBB and/or abnormal vascularity.
Timing and dose of gadolinium contrast depend on the scan type and patient factors, including kidney function.
Label provides a specific recommended dose (0.2 mL/kg) and renal-impairment warning, but does not support 'dose depends on kidney function' or 'scan type' dependence in the excerpt.
Mild side effects such as nausea, headache, or injection-site reactions may occur with gadoterate meglumine.
Injection-site reactions are referenced (5.6), but nausea/headache are not present in the provided excerpts.
There are multiple GBCA options used for MRI.
Not unsupported; however, if treated strictly, label only compares specific agents and does not state 'multiple options' as a general claim. (If counted as supported, remove from this list.)
GBCA options have different stability profiles and dosing considerations.
No stability-profile or dosing-consideration differences are described in the provided excerpts.
Gadolinium agents differ in their chemical structure and stability.
Label excerpt only mentions 'macrocyclic GBCAs' and retention comparison; it does not explicitly state chemical-structure/stability differences.
Contradictions
Important Omissions
Failure to explicitly state that Clariscan is NOT approved for intrathecal use and that intrathecal GBCA can cause serious adverse reactions including death, coma, encephalopathy, and seizures.
Importance:
High
Failure to explicitly include nephrogenic systemic fibrosis (NSF) risk and the instruction to avoid use in certain patients unless essential and to adhere to dosing/elimination timing in highest-risk patients.
Importance:
High
Failure to include hypersensitivity/anaphylaxis warning timing (within minutes) and that such reactions have been reported.
Importance:
Moderate
Failure to include extravasation/injection-site patency instruction (ensure catheter and venous patency).
Importance:
Moderate
Failure to include the contraindication: history of clinically important hypersensitivity reactions to Clariscan.
Importance:
Moderate
Failure to include the recommended dose and route specifics: 0.2 mL/kg (0.1 mmol/kg) IV bolus injection.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
The response omits several label-critical safety elements (intrathecal non-approval/serious neurotoxicity, NSF risk guidance, hypersensitivity/anaphylaxis, contraindication, and exact IV dosing). While it includes some kidney-caution messaging, it does not capture key instructions and warnings required by the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Material omissions of label-required critical safety information (intrathecal non-approval, NSF guidance, hypersensitivity, contraindication) and missing dosing specifics; plus some indications/side-effect examples not supported by provided label excerpts.
Suggested Improvement
Restrict claims to label-supported indication (IV MRI to detect BBB disruption/abnormal vascularity) and include key warnings: Clariscan not approved for intrathecal use; NSF risk/avoidance and screening; hypersensitivity/anaphylaxis; contraindication for prior clinically important hypersensitivity; and dosing/route (0.2 mL/kg IV bolus). Avoid adding tumor/infection indications or nausea/headache unless supported by the label text provided.